Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 2/20 | 0.78 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.65 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.53 |
| ▸ | HTR1A | P08908 | 3/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.52 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2523551 | 1.00 | HRH1 (0.78) | HRH1CHRNB2CHRNA4SLC6A2HTR1A | |
| SCHEMBL14828522 | 1.00 | HRH1 (0.78) | HRH1CHRNB2CHRNA4SLC6A2HTR1A | |
| Hydrochloric Acid SCHEMBL1769019 | 0.98 | HRH1 (0.75) | HRH1CHRNB2CHRNA4SLC6A2HTR1A | |
| Hydrochloric Acid SCHEMBL795806 | 0.98 | HRH1 (0.75) | HRH1CHRNB2CHRNA4SLC6A2HTR1A | |
| Hydrochloric Acid SCHEMBL796443 | 0.98 | HRH1 (0.75) | HRH1CHRNB2CHRNA4SLC6A2HTR1A | |
| SCHEMBL4317978 | 0.93 | HRH1 (0.68) | HRH1CHRNB2CHRNA4SLC6A2HTR1A | |
| SCHEMBL4317973 | 0.93 | HRH1 (0.68) | HRH1CHRNB2CHRNA4SLC6A2HTR1A | |
| Hydrochloric Acid SCHEMBL4317942 | 0.91 | HRH1 (0.66) | HRH1CHRNB2CHRNA4SLC6A2HTR1A | |
| Hydrochloric Acid SCHEMBL4317936 | 0.91 | HRH1 (0.66) | HRH1CHRNB2CHRNA4SLC6A2HTR1A | |
| SCHEMBL17593357 | 0.89 | CHRNB2 (0.67) | HRH1CHRNB2CHRNA4SLC6A2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022096-A1 | NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS | GENECODE (EE) | 2026-01-22 | — | — | US | claimed |
| EP-4561994-A1 | NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS | Genecode (EE) | 2025-06-04 | — | — | EP | claimed |
| CN-119948015-A | Novel sulfonamides and their use as neuroprotective and/or nerve repair agents | 基因密码公司 | 2025-05-06 | — | — | CN | claimed |
| WO-2024023284-A1 | NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS | GENECODE (EE) | 2024-02-01 | — | — | WO | claimed |
| US-20130245064-A1 | NOVEL NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2013-09-19 | — | — | US | claimed |
| EP-2635554-A2 | NOVEL NEUROTRYPSIN INHIBITORS | Neurotune AG (CH) | 2013-09-11 | — | — | EP | claimed |
| WO-2012059443-A2 | NOVEL NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2012-05-10 | — | — | WO | claimed |
| US-20260022096-A1 | NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS | GENECODE (EE) | 2026-01-22 | — | — | US | disclosed |
| EP-4635494-A2 | AMIDO HETEROAROMATIC COMPOUNDS | Astrazeneca AB (SE) | 2025-10-22 | — | — | EP | disclosed |
| EP-4514782-B1 | AMIDO HETEROAROMATIC COMPOUNDS USEFUL IN THE TREATMENT OF LIVER DISEASES | ASTRAZENECA AB (SE) | 2025-09-10 | — | — | EP | disclosed |
| US-12391663-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS AG (CH) | 2025-08-19 | — | — | US | disclosed |
| EP-4561994-A1 | NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS | Genecode (EE) | 2025-06-04 | — | — | EP | disclosed |
| US-12291524-B2 | Amido heteroaromatic compounds | ASTRAZENECA AB (SE) | 2025-05-06 | — | — | US | disclosed |
| EP-1444202-B1 | NOVEL METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-10-15 | — | — | EP | disclosed |
| EP-1961752-A2 | Piperidine Compounds | Speedel Experimenta AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| US-20070010511-A1 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2007-01-11 | — | — | US | disclosed |
| EP-1670760-A1 | ORGANIC COMPOUNDS | Speedel Experimenta AG (CH) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005061457-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-07-07 | — | — | WO | disclosed |
| US-5472958-A | 2-((nitro)phenoxymethyl) heterocyclic compounds that enhance cognitive function | ABBOTT LABORATORIES (US) | 1995-12-05 | — | — | US | disclosed |
| EP-0338331-B1 | 1,3 DISUBSTITUTED PYRROLIDINES | BAYER AG (DE) | 1992-10-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12291524-B2 | Amido heteroaromatic compounds | CYP7A1, SLC10A1, CYP11B2 | HRH1 456/4885CHRNB2 4264/4885CHRNA4 4701/4885 |
| US-12391663-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | HRH1 802/4885CHRNB2 236/4885CHRNA4 852/4885 |
| US-20070010511-A1 | Organic compounds | REN, ACE, ACE2 | HRH1 1092/4885CHRNB2 3971/4885CHRNA4 4298/4885 |
| US-20260022096-A1 | NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS | CNR1, CDR2, SMN1; SMN2 | HRH1 85/4885CHRNB2 95/4885CHRNA4 212/4885 |
| US-20130245064-A1 | NOVEL NEUROTRYPSIN INHIBITORS | PRSS12, NLN, MTPN | HRH1 720/4885CHRNB2 14/4885CHRNA4 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.